Skip to main content

Edesa Biotech, Inc.

corporate_fare Company Profile

Edesa Biotech, Inc.

EDSA·NASDAQ·Life Sciences·CIK 0001540159

Edesa Biotech, Inc. is a biopharmaceutical company that develops treatments for inflammatory and immune-related diseases. The company focuses on acquiring, developing, and commercializing drug candidates based on mechanisms of action that have shown proof-of-concept in human subjects. Edesa Biotech prioritizes diseases with strong scientific rationale, no approved therapies or unmet medical needs, and large addressable market opportunities. The company's clinical pipeline is concentrated in two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa Biotech is developing EB06, an anti-CXCL10 monoclonal antibody candidate, for vitiligo, an autoimmune disorder causing skin depigmentation. CXCL10 is known to be involved in vitiligo, and its neutralization has prevented and reversed depigmentation in animal models. EB06 has shown a favorable safety and tolerability profile. Health Canada has approved a Phase 2 proof-of-concept study of EB06 in patients with moderate-to-severe nonsegmental vitiligo, and discussions are ongoing with the U.S. Food and Drug Administration (FDA) for the same study. Enrollment is anticipated to begin by midyear 2026, subject to regulatory approval. The Medical Dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), which is currently at the partnering stage. Edesa Biotech's most advanced Respiratory drug candidate is EB05 (paridiprubart), a Host-Directed Therapeutic (HDT) designed to modulate the body's immune response to infectious diseases or chemical agents. In October 2025, paridiprubart met primary and secondary endpoints with statistical significance, showing clinically meaningful improvement in survival and recovery, in a truncated Phase 3 clinical study of hospitalized patients with Acute Respiratory Distress Syndrome (ARDS). Paridiprubart is also being evaluated in an ongoing U.S. study.

Edesa Biotech, Inc. (NASDAQ:EDSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for EDSA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholders Approve 8.4% Potential Dilution for Equity Plan
  • CEO Shifts 90% of Salary to Stock Amidst Going Concern Warning
  • Edesa Biotech Reports Wider Q2 Loss, But Phase 3 Drug Shows Significant Mortality Reduction
  • Edesa Biotech Reports Widening Losses, Short Cash Runway, and Going Concern Warning
  • Edesa Biotech Seeks Shareholder Approval for Significant Equity Plan Expansion

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$7.19M
Op. Cash Flow
-$7.32M
Operating Income
-$7.91M
Cash & Equivalents
$10.79M
Debt / Equity
0.00×
Shares Outstanding
7.14M sh
Source: 10-K · filed 2025-12-12 · accession 0001171843-25-007914
$1.99 -0.50% today
52-week range · as of 2026-11-17 $0.72 – $20.32
Market cap
$27.02M
Volume
121.2K (0.0× avg)
3-mo avg 3M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EDSA - Filings & News (Page 2)

EDSA
May 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.22
Real-time Price: $1.99 info
Change: -$5.23 (-72%) info
Market Cap: $27.023M info
EDSA
May 15, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.35
Real-time Price: $1.99 info
Change: -$12.36 (-86%) info
Market Cap: $27.023M info
EDSA
May 14, 2026, 4:52 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $14.61
Real-time Price: $1.99 info
Change: -$12.62 (-86%) info
Market Cap: $27.023M info
EDSA
May 14, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $14.61
Real-time Price: $1.99 info
Change: -$12.62 (-86%) info
Market Cap: $27.023M info
EDSA
Apr 03, 2026, 4:33 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $6.05
Real-time Price: $1.99 info
Change: -$4.06 (-67%) info
Market Cap: $27.023M info
EDSA
Mar 05, 2026, 5:01 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $1.99 info
Change: -$1.81 (-48%) info
Market Cap: $27.023M info
EDSA
Mar 04, 2026, 5:01 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $4.34
Real-time Price: $1.99 info
Change: -$2.35 (-54%) info
Market Cap: $27.023M info
EDSA
Mar 02, 2026, 7:03 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $1.99 info
Change: -$0.3895 (-16%) info
Market Cap: $27.023M info
EDSA
Mar 02, 2026, 5:11 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $1.99 info
Change: -$0.3895 (-16%) info
Market Cap: $27.023M info
EDSA
Mar 02, 2026, 5:05 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $1.99 info
Change: -$0.3895 (-16%) info
Market Cap: $27.023M info
EDSA
Feb 24, 2026, 9:21 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9298
Real-time Price: $1.99 info
Change: +$1.06 (+114%) info
Market Cap: $27.023M info
EDSA
Feb 13, 2026, 4:45 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.9601
Real-time Price: $1.99 info
Change: +$1.03 (+107%) info
Market Cap: $27.023M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets